DB-1310 by Duality Biologics (Shanghai) for Human Epidermal Growth Factor Receptor 2 Positive Breast Cancer (HER2+ Breast Cancer): Likelihood of Approval

DB-1310 is under clinical development by Duality Biologics (Shanghai) and currently in Phase II for Human Epidermal Growth Factor Receptor 2 Positive Breast Cancer (HER2+ Breast Cancer).

Robotic device could revolutionize how women monitor their breast health

A device has been created that could carry out Clinical Breast Examinations (CBE).

October 4, 2023

Shareholders approve the sale of Evolva AG to Lallemand Inc. Swiss subsidiary at extraordinary general meeting – Biotech Investments

Evolva Holding SA / Key word(s): AGMEGMShareholders approve the sale of Evolva AG to Lallemand Inc. Swiss subsidiary at extraordinary general meeting21.12.2023 / 17:45 CET/CEST

December 22, 2023

Insomnia linked to higher ovarian cancer risk and mortality in new genetic study

Researchers found a significant genetic link between insomnia and increased risk and mortality in epithelial ovarian cancer (EOC).

June 5, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.